Szymon Piotr Baluszek

Dr. Szymon Piotr Baluszek

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SBSzymon Piotr Baluszek
Szymon Piotr Baluszek
PKPaulina Kober
Paulina Kober
IMIzabella Myśliwy
Izabella Myśliwy
AOArtur Oziębło
Artur Oziębło
TMTomasz S. Mandat
Tomasz S. Mandat
MBMateusz Bujko
Mateusz Bujko
Background: Meningiomas are common intracranial tumors in adults. Most are benign WHO grade I (GI) tumors, while approximately 20% are diagnosed as more aggressive WHO grade II (GII) and grade III (GIII) meningiomas. The study aimed to identify genes with tumor grade-related expression and to assess their functional relevance. Methods: RNA sequencing (RNA-seq) was performed to analyze transcriptomes of benign meningothelial (n = 19) and fibrous (n = 11), atypical (n = 18) and anaplastic (n = 12) meningiomas. The data were analyzed for differential genes expression and Gene Set Enrichment Analysis (GSEA). A deposited scRNA-seq dataset was used to define meningioma cellular composition and cell type-specific gene expression enabling deconvolution of RNA-seq data. Results: Unsupervised analysis revealed three tumor clusters corresponding to the histological subtypes of meningothelial (GI), fibrous (GI) and atypical/anaplastic (GII/GIII) meningiomas. Differential analysis identified 5518 protein-coding genes with grade-related changes in expression. GSEA showed that high-grade meningiomas were enriched for processes of cell proliferation, ribosome biogenesis, and metabolism, whereas benign tumors were enriched for cell morphogenesis, transmembrane ion transport, and immune regulation. PGK1 was the most significantly grade-related gene and increased expression of phosphoglycerate kinase 1 in GII and GIII tumors was confirmed by immunohistochemistry. Deconvolution of RNA-seq data revealed grade-related changes in the tumor microenvironment, notably a progressive decrease in border-associated macrophages from WHO GI to GIII tumors. Conclusions: In our study, we characterized key genes and processes dysregulated in high-grade meningiomas, including less understood mechanisms such as metabolic reprogramming, disrupted ion transport, altered immune regulation, and differences in the tumor microenvironment between benign and aggressive tumors.

15 January 2026 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
SCSalwador Cyranowski
Salwador Cyranowski
MZMalgorzata Zawadzka
Malgorzata Zawadzka
Mitrajit GhoshMitrajit Ghosh
Mitrajit Ghosh
BWBartosz Wojtas
Bartosz Wojtas
AMAnna Malik
Anna Malik
BBozena Kaminska
Bozena Kaminska
Chitinase-3-like protein 1 (CHI3L1) is a secreted, non-enzymatic glycoprotein that interacts with cell-surface and extracellular-matrix proteins, proteoglycans, and polysaccharides. Many studies reported the overexpression of CHI3L1 in various cancers, but its exact role in tumorigenesis/cancer progression remains elusive. We performed a comprehensive analysis of CHI3L1 expression in public repositories including single-cell RNAseq datasets to determine the cellular source of CHI3L1 expression in gliomas. The highest CHI3L1 expression was detected in glioblastoma (GBM), a high-grade diffusive brain tumor with dismal survival prognosis. CHI3L1 knockout (KO) in human U87-MG glioma cells grossly affected transcriptional profiles and in vitro invasiveness of these cells, and strongly reduced the growth of intracranial U87-MG tumors in athymic mice. CHI3L1 KO in glioma cells resulted in normalization of tumor vasculature. Co-culture of CHI3L1 KO glioma cells with astrocytes upregulated aquaporin 4 (AQP4) in p38/MAPK and IL-1β/NFκB-dependent manner. Diminished infiltration of glioma-associated myeloid cells in CHI3L1 KO tumors was associated with reduction in SPP1 expression in CHI3L1 KO cells. Altogether, we demonstrate that CHI3L1 depletion affects several mechanisms crucial for GBM progression, therefore its targeting represents a novel strategy to treat GBM patients.

18 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSzymon Piotr Baluszek
Szymon Piotr Baluszek
PKPaulina Kober
Paulina Kober
RWRenata Woroniecka
Renata Woroniecka
NMNatalia Maławska
Natalia Maławska
MWMichał Wągrodzki
Michał Wągrodzki
MBMateusz Bujko
Mateusz Bujko
Chordoma, a rare sarcoma of notochordal origin, exhibits slow growth and local aggressiveness. While copy-number (CN) events are recognized as key chordoma drivers, no comprehensive classification, based on CN, has yet been developed. Here, we establish a robust, reproducible genomic subtyping of chordoma, based on CN events. Two independent skull base chordoma cohorts (N=32,N=71) were analyzed, utilizing distinct analytical platforms, DNA methylation microarrays and whole-genome sequencing, both controlled for B-allele frequencies. Samples were clustered using unsupervised hierarchical methods. The CN events defined four consistent molecular clusters across both cohorts: C1 (CN-stable), C9 (chromosomal losses, especially of chr9/ CDKN2A ), C7 (chr7 gain), and C2 (gains of chr2 and chr7). The findings were validated in fluorescence in situ hybridization (FISH) with concordance of 84-89%. The CN clusters explain 31-33% of the RNA-sequencing transcriptional variance. Moreover, the C2 cluster showed up-regulation of Sonic Hedgehog signaling and clusters C2 and C9 were enriched in cell-cycle-related genes. The proposed CN clusters correlate with existing chordoma classificators e.g. chromosomal instability (CIN), mutation burden, immune score, and methylation clusters. Furthermore, comparison with over 2,000 sarcomas highlighted CN patterns more common in chordoma (i.e. chr1q, chr2, chr7 gains and chr1p, chr3, chr9, chr10, chr13, chr14, chr18 losses) but also revealed shared aberrations, e.g. chr22 loss shared with Gastrointestinal Stromal Tumours (GISTs). This study provides a unifying classification for skull base chordoma, linking distinct genomic architectures to specific transcriptional programs and potential therapeutic vulnerabilities.

8 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AEAleksandra Ellert-Miklaszewska
Aleksandra Ellert-Miklaszewska
PPPaulina Pilanc-Kudlek
Paulina Pilanc-Kudlek
KPKatarzyna Poleszak
Katarzyna Poleszak
ARAdria-Jaume Roura
Adria-Jaume Roura
SCSalwador Cyranowski
Salwador Cyranowski
BBozena Kaminska
Bozena Kaminska
Immune checkpoint inhibitors (ICI) presented clinical benefits in many cancer patients but invariably fail in glioblastoma (GBM), the most common and deadly primary brain tumor. Lack of ICI efficacy in GBM is attributed to the accumulation of immunosuppressive myeloid cells that create the “cold” tumor microenvironment (TME) impeding infiltration and activation of effector T cells. We developed a designer RGD peptide that hindered glioma-instigated, integrin-mediated pro-tumoral reprogramming of myeloid cells and blocked microglia-dependent invasion of human and mouse glioma cells in co-cultures in vitro . Intratumorally-delivered RGD alone did not reduce glioma growth in syngeneic mice but prevented the emergence of immunosuppressive myeloid cells and led to peritumoral blood vessels normalization. Furthermore, combining RGD with immunotherapy using PD-1 blockade reduced tumor growth, led to upsurge of proliferating, interferon-ɣ producing CD8 + T cells and depleted regulatory T cells. Transcriptomic profiles of myeloid cells were altered by the combined treatment, consistently with the restored “hot” inflammatory TME and boosted immunotherapy responses. RGD modified the phenotypes of myeloid cells in human gliomas in nude mice. Thus, combining the integrin blockade with ICI reinvigorates antitumor immunity and paves the way to improve immunotherapy outcomes in GBM.

22 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
SBSzymon Piotr Baluszek
Szymon Piotr Baluszek
PKPaulina Kober
Paulina Kober
MBMateusz Bujko
Mateusz Bujko
Chordoma is a rare malignant neoplasm of the axial skeleton, arising from notochordal remnants. No approved systemic therapies exist, and the 10-year overall survival is below 60%. Accurate molecular and pathological classification is a prerequisite for improved prognostication and the identification of actionable therapeutic targets; however, molecular classification of chordoma remains significantly less advanced than that of other neoplasms. This narrative review synthesizes proposed classification frameworks for chordoma across histological, radiological, surgical, genomic, epigenomic, transcriptomic, and proteomic domains. PubMed and CENTRAL were searched on 1 February 2026 using five queries: ‘chordoma classification’, ‘chordoma DNA sequencing’, ‘chordoma RNA sequencing’, ‘chordoma methylation’, and ‘chordoma copy number’. Original research articles describing more than one patient and reporting a classification or subtyping framework were included; review articles, case reports, and non-English publications were excluded. Sample size and the use of a validation dataset were identified for each study. Results were synthesized qualitatively. A total of 108 studies encompassing 6349 individuals were included. Across six domains, four cross-cutting themes with prognostic and potential theranostic value emerged: copy number alterations, particularly CDKN2A/B loss; SWI/SNF complex dysfunction; stroma–tumor ratio; and immune microenvironment heterogeneity.

Verified
Journal Article
Open access
PDF file
PKPaulina Kober
Paulina Kober
SBSzymon Piotr Baluszek
Szymon Piotr Baluszek
BMBeata Joanna Mossakowska
Beata Joanna Mossakowska
IMIzabella Myśliwy
Izabella Myśliwy
BTBiniyam Tsegaye
Biniyam Tsegaye
MBMateusz Bujko
Mateusz Bujko
Meningiomas are the most common intracranial tumors. DNA methylation analysis in benign and aggressive meningiomas showed decreased MIR21 methylation and overexpression of hsa-miR-21-5p in atypical and anaplastic tumors. Transcriptomic analysis of distinct WHO grade meningiomas showed multiple predicted hsa-miR-21-5p target genes as differentially expressed. They were mainly related to processes of intercellular and intracellular signaling. Intercellular communication in meningioma was investigated using the deposited scRNA-seq dataset and deconvolution of our RNA-seq data. We found WHO grade-related differences in the microenvironment including inverse correlation between the count of border-associated macrophages (BAM) and the level of hsa-miR-21-5p. Single-cell transcriptomics suggests the role of interleukin 6 in direct communication between tumor cells and BAMs. IL6R and IL6ST are predicted targets of hsa-miR-21-5p downregulated in atypical/anaplastic meningiomas. IL6R downregulation was also confirmed by immunohistochemistry. Hsa-miR-21-5p enhanced proliferation and viability of KT21-MG1 meningioma cells and showed a regulatory effect on IL6R, IL6ST and other predicted target genes TIMP3, PIK3R, RHOB, and SASH1 by interacting with 3′UTRs. DNA hypomethylation-related overexpression of hsa-miR-21-5p contributes to aggressive meningioma growth by interaction with multiple target genes, and probably affects microenvironment communication between meningioma cells and BAMs by lowering the IL6R level in tumor tissue.